Elsevier

Oral Oncology

Volume 40, Issue 2, February 2004, Pages 228-230
Oral Oncology

CASE REPORT
Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour

https://doi.org/10.1016/j.oraloncology.2003.08.003Get rights and content

Abstract

The suppression and eradication of malignant tumours by targeting the endothelial cells of the tumour is one of the rapidly evolving new approaches to cancer therapy. Head and neck tumours, because of their high levels of vascularization, present themselves as ideal candidates for such antiangiogenic strategies. We report a heavily pretreated patient with a tumour 15 cm in diameter representing fourth relapse of squamous cell carcinoma, which had its origin in the upper left jaw. The patient was treated with the antiangiogenetic, cyclic peptide, EMD 121974 [cilengitide] (600 mg/m2 over 60 minutes iv) on day 1 and 4 in combination with gemcitabine (1000 mg/m2 over 30 minutes) administered days 1 and 8 every 3 weeks for five months, and a partial remission was achieved. This resulted in a clinical improvement in the ability of the patient to eat and smell. The patient remained stable for 12 months on cilengitide mainenance therapy, with no tendancy towards spontaneous bleeding. This clinical case demonstrates the clinical efficacy of the antiangiogenetic agent cilengitide, in combination with gemcitabine, in inhibiting rapid growth of highly vascularized tumour and highlights the potential of this new therapeutic agent

References (4)

There are more references available in the full text version of this article.

Cited by (86)

  • Tumor adhesion molecule targeting for breast cancer nanomedicine

    2022, Targeted Nanomedicine for Breast Cancer Therapy
  • Integrins as attractive targets for cancer therapeutics

    2021, Acta Pharmaceutica Sinica B
    Citation Excerpt :

    This αv inhibitor apparently acts by inhibiting the FAK/SRC/AKT pathway and triggering apoptosis in endothelial cells. Preclinical studies have revealed positive antiangiogenic effects in vitro136 and antitumor effects in vivo against melanoma, and also in head and neck cancer, breast cancer, and brain tumor137,138. Cilengitide has been used in trials for the treatment of sarcoma, glioma, lymphoma, leukemia, and lung cancer.

  • PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting αv integrin/FAK/Src signaling in oral squamous cell carcinoma cells

    2019, Acta Pharmaceutica Sinica B
    Citation Excerpt :

    The overall pharmacological effect of RGD-containing peptidic agents is likely to be mediated via dual mechanisms, direct antitumor activity as well as interference with endothelial cell functions in cancer vasculature24. Given the highly vascularized nature of HNSCC, targeting neoangiogenesis could be a reasonable approach for depriving tumor of adequate nutrition and improving patient outcomes25. In such a context, our attention has been paid to a novel RGD-based PEP06 polypeptide, originating from the active fragment of natural inhibitor of angiogenesis endostatin.

  • Epigenetic regulation and targeting of ECM for cancer therapy

    2022, American Journal of Physiology - Cell Physiology
View all citing articles on Scopus
View full text